Strain Profile
Save
Clostridium butyricum CBM588
◑
Environmental
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Clostridium butyricum MIYAIRI 588 (CBM588) is a spore-forming, butyrate-producing bacterium studied in the context of gut health and, more recently, oncology. In vitro studies have characterized its butyrate production pathway and anti-inflammatory mechanisms, and animal studies have examined intestinal recovery following antibiotic use. Phase I clinical trials have examined CBM588 as an adjunct to immunotherapy regimens for metastatic renal cell carcinoma. This strain has a documented history of use as a probiotic in Japan and is taxonomically distinct from pathogenic Clostridium species. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 70 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+3 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 18 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
79 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
OBSERVATIONAL
2026
RCT
2026
REVIEW
2026
OBSERVATIONAL
2026
RCT
2025
OBSERVATIONAL
2025
RCT
2025
OBSERVATIONAL
2025
OBSERVATIONAL
2025
IN_VITRO
2025
RCT
2025
OBSERVATIONAL
2025
RCT
2025
ANIMAL
2025
OTHER
2025
RCT
2025
OBSERVATIONAL
2025
OBSERVATIONAL
2025
RCT
2024
OBSERVATIONAL
Browse all 79 papers →
A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer
· Frontiers in Immunology
Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).
· Journal of Clinical Oncology
Potential Health Benefits of Probiotic Strains of Clostridium butyricum
· Applied Microbiology
Abstract 6476: Microbiome modulation via CBM588 dampens T cell exhaustion in patients with metastatic renal cell carcinoma on dual immune checkpoint blockade
· Cancer Research
First results of a dose-escalation study evaluating Clostridium butyricum MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).
· Journal of Clinical Oncology
A probiotic bacterium modulates antitumor γδ T-cell responses in lung cancer
· bioRxiv (Cold Spring Harbor Laboratory)
Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial.
· Journal of Clinical Oncology
Probiotic Prophylaxis With Clostridium butyricum for Postoperative Infections Following Lung Resection: A Propensity Score–Weighted Analysis
· The Annals of Thoracic Surgery
Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of Clostridium butyricum CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study
· Microorganisms
A rapid genome-proteome approach to identify rate-limiting steps in the butyrate production pathway in probiotic Clostridium butyricum, CBM588
· Anaerobe
Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.
· Journal of Clinical Oncology
Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study
· International Journal of Colorectal Disease
Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial
· Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy
· International Journal of Cancer
Management of Recurrent Clostridium difficile Infection in a 75-Year-Old Woman with Multiple Comorbidities and Marked Anxiety Using a Combined Therapeutic Approach
· Preprints.org
Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
· Journal of Clinical Oncology
Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination.
· Journal of Clinical Oncology
Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study
· Cancer Reports
Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial
· Cell Reports Medicine
Innovative strategies for the rapid restoration of intestinal function in patients undergoing abdominal surgery: use of probiotics. Pilot study of 15 patients
· Minerva Gastroenterology
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
Source →Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).· Journal of Clinical Oncology · 2026
-
[2]
PMID 40633539 →Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial· Cell Reports Medicine · 2025
-
[3]
Source →Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.· Journal of Clinical Oncology · 2025
-
[4]
PMID 40431311 →Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of Clostridium butyricum CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study· Microorganisms · 2025
-
[5]
Source →Long-term clinical outcomes with nivolumab/ipilimumab with or without Clostridium butyricum MIYAIRI588 in metastatic renal cell carcinoma (mRCC): A randomized phase Ib clinical trial.· Journal of Clinical Oncology · 2025
-
[6]
PMID 41425719 →Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial· Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2025
-
[7]
Source →A probiotic bacterium modulates antitumor γδ T-cell responses in lung cancer· bioRxiv (Cold Spring Harbor Laboratory) · 2025
-
[8]
PMID 37658670 →Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus· Annals of the New York Academy of Sciences · 2023
-
[9]
Source →Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.· Journal of Clinical Oncology · 2023
-
[10]
PMID 35899808 →Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma· Clinical and Translational Medicine · 2022